ArticleBMC infectious diseases2025
Plasma proteomic signatures in HIV-infected individuals post-SARS-CoV-2 infection.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term immunological effects of prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in people living with Human Immunodeficiency Virus (HIV) remain poorly understood. This study aimed to characterize plasma proteomic alterations associated with previous SARS-CoV-2 infection in HIV-infected individuals and to identify potential biomarkers and affected pathways. High-throughput liquid chromatography–tandem mass spectrometry (LC–MS/MS) was performed on plasma obtained from three groups: HIV-infected individuals with documented prior SARS-CoV-2 infection, HIV-monoinfected individuals, and healthy controls. A total of 13,675 proteins were identified. Hierarchical clustering and sparse partial least squares discriminant analysis revealed distinct proteomic profiles in the prior-SARS-CoV-2 group. Ten proteins with the highest discriminatory power—PRR11, TEX14, METTL9, NMD3, PXT1, CRISP2, MELK, SPF27, GCP6, and GTPBP8—were associated with cell cycle regulation, RNA processing, apoptosis, mitochondrial function, and cytoskeletal organization. Subcellular localization indicated predominant nuclear and cytoplasmic involvement, suggesting alterations in transcriptional regulation and intracellular structural dynamics. These signatures imply that preceding SARS-CoV-2 exposure may compound HIV-associated immune dysregulation and disrupt cellular homeostasis. The findings offer novel molecular insights into the persistent biological impact of SARS-CoV-2 in the context of HIV and identify candidate proteomic biomarkers with potential utility for risk stratification and targeted intervention in immunocompromised populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.